Homepage
Medication Guide
What are the Indications of Benidipine Hydrochloride (Coniel)?
Benidipine Hydrochloride (Coniel) is a long-acting calcium channel blocker belonging to the dihydropyridine class of antihypertensive drugs, and is widely indicated for the treatment of hypertension a...
520
Wednesday, December 24th, 2025, 10:34
Dosage and Administration & Recommended Dose of Benidipine Hydrochloride (Coniel)
Benidipine Hydrochloride (Coniel) is a long-acting dihydropyridine calcium channel blocker, which is widely used clinically for the treatment of hypertension and angina pectoris. It inhibits calcium i...
557
Wednesday, December 24th, 2025, 10:28
Side Effects of Enasidenib
Enasidenib is a targeted therapy for adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring a specific genetic mutation (IDH2 mutation).Side Effects of EnasidenibCommon Side...
510
Tuesday, December 23rd, 2025, 10:24
What are the Precautions for Enasidenib Administration?
Enasidenib is an isocitrate dehydrogenase-2 (IDH2) inhibitor that offers a targeted treatment option for patients with relapsed or refractory acute myeloid leukemia (AML).What are the Precautions for ...
507
Tuesday, December 23rd, 2025, 10:21
Dosage and Administration, Recommended Dose of Enasidenib
As an isocitrate dehydrogenase-2 (IDH2) inhibitor, Enasidenib offers a targeted treatment option for patients with relapsed or refractory acute myeloid leukemia (AML). Its unique mechanism of action t...
510
Tuesday, December 23rd, 2025, 10:09
What Are the Indications for Enasidenib?
Enasidenib is an oral isocitrate dehydrogenase-2 (IDH2) inhibitor, which was first approved for marketing in the United States in 2017 for the treatment of specific types of acute myeloid leukemia (AM...
514
Tuesday, December 23rd, 2025, 09:30
What Are the Procurement Channels for Enasidenib?
Enasidenib is a targeted drug indicated for relapsed or refractory acute myeloid leukemia (AML) with IDH2 mutation, and its trade name is IDHIFA. Given its specific indications and prescription-only n...
507
Tuesday, December 23rd, 2025, 09:25
Adverse Reactions of Pralsetinib (Gavreto)
Pralsetinib (Gavreto) is a targeted therapy for RET fusion-positive tumors. While delivering therapeutic benefits to patients, it is also associated with potential risks that cannot be ignored.Adverse...
527
Monday, December 22nd, 2025, 09:44
What Are the Precautions for Pralsetinib (Gavreto) Administration?
Pralsetinib (Gavreto) is a new-generation highly selective RET inhibitor, offering a breakthrough treatment option for patients with RET fusion-positive non-small cell lung cancer and thyroid cancer.W...
511
Monday, December 22nd, 2025, 09:41
Dosage and Administration, Recommended Dose of Pralsetinib (Gavreto)
Pralsetinib (Gavreto) is a kinase inhibitor targeting RET gene fusions, and it demonstrates significant value in the treatment of metastatic RET fusion-positive non-small cell lung cancer and thyroid ...
510
Monday, December 22nd, 2025, 09:34
37 / 221
2204 in total
Departments
Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved